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Introduction
Fibrosis of epithelial parenchymal organs and
end-stage organ failure represent the final common
pathways of many chronic diseases and are major de-
terminants of morbidity/mortality worldwide. Com-
parison studies of pulmonary, hepatic and renal fi-
brosis have identified several common mechanisms,
including a critical role for the cytokine transforming
growth factor-beta and the generation of reactive
oxygen species (1). Idiopathic pulmonary fibrosis
(IPF) is a progressive and devastating illness with a
mean survival of less than 5 years from the onset of
symptoms. IPF epidemiology is on the rise but un-
derlying pathogenetic mechanisms are not clearly
elucidated (2). At present, IPF is considered as an
epithelial/fibroblastic disorder resulting from an un-
abated continuation of the repair process in response
to recurrent episodes of epithelial injury (3). There is
evidence that oxidative stress may be a key player in
this scenario (4), conversely, the role of inflammation
still remains largely controversial while emerging da-
ta suggest the immune system involvement (5). IPF
natural history may also differ among patients due to
a significant heterogeneity in disease behavior. As a
consequence, any effort tailored at the characteriza-
tion of IPF sub-phenotypes is mandatory.
To address whether the liver may be involved,
apart from the lung, in the challenging IPF clinical
picture, the aim of the present study was to evaluate
liver stiffness values in clinically stable IPF patients.
Novel non-invasive tests such as transient ultrasound
elastography (TUE) are widely used to stage liver fi-
brosis as an alternative to liver biopsy, and this tech-
nology has recently been approved in the US (6).
TUE has been proposed as a possible tool for diag-
nosis and monitoring of non-significant fibrosis or
severe fibrosis/cirrhosis in patients with chronic he-
patitis C virus (HCV) infection. Liver stiffness val-
ues have also been significantly correlated with
histopathological staging of liver biopsy, with excel-
lent accuracy in distinguishing absent/mild and ad-
vanced fibrosis (7).
Case series report
Twenty-nine consecutive Italian IPF patients
were enrolled between June 2012 and December
2013. Diagnostic preliminaries included clinical his-
tory, physical examination, routine and autoimmu-
nity blood tests, lung function testing, arterial blood
gases analysis, incremental thin-section high resolu-
tion computed tomography scan (HRCT) of the
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thorax and echocardiography. The 6 minute walk
test and fiberoptic bronchoscopy were performed in
selected cases. Disease diagnosis was made accord-
ing to the recent American Thoracic Society/Euro-
pean Respiratory Society consensus statement (2).
Demographics and clinical features are reported in
Table 1. Fifteen age- and sex-matched healthy vol-
unteers were recruited among hospital staff as con-
trol group. Lung function parameters are reported in
Table 2. The composite physiologic index (CPI) (8),
the GAP score (9) and the Kazerooni visual qualita-
tive score of disease extension on HRCT scan (10)
Table 1. Demographics and clinical characteristics of IPF patients
Parameter IPF patients Controls
Gender 24M/5F 12M/3F
Age (years) 67±8.3 64±3.9
BMI (Kg/m2) 28±1.7 27±1.9
Smokers/former smokers/never smokers 0/19/10 0/5/10
Comorbidities:
- systemic arterial hypertension 8 (27.5%)
- chronic ischemic heart disease 6 (20%)
- type II diabetes 6 (20%)
- combined pulmonary emphysema 2 (7%)
- GERD 10 (34%)
- pulmonary arterial hypertension* 4 (14%)
Treatments for IPF:
- pirfenidone (2403 mg/day), and/or 9 (31%)
- NAC (1800 mg/day) 7 (24%)
- other (experimental trial drugs) 2 (7%)
- no therapy 15 (52%)
Long-term oxygen therapy 14 (48%) -
Data are expressed as mean±SD or as absolute number (percentage)
Abbreviations: BMI= body mass index; GERD= gastro-esophageal reflux disease; NAC= N-acetylcysteine.
* Likely/possible pulmonary hypertension was diagnosed by means of echocardiography according to recent guidelines (17) with an esti-
mated mean systolic pulmonary artery pressure±SD of 30.5 ± 6.6 mmHg.
Table 2. Respiratory function parameters and thorax HRCT scoring in IPF patients
Parameter IPF patients Controls
pO2 (mmHg) (21% FiO2 at rest) 69.5±13.6; 71.6 [63.8-75.3] -
% sO2 (21% FiO2 at rest) 92.3±5.7; 95 [89.9-94.7] 98±1.6; 97 [96-100]
FVC (L) 3.1±4.0; 2.4 [1.3-4.9] 3.5±0.8; 3.4 [2.7-4.0]
FVC (% predicted) 69.8±18.7; 69 [61.5-78.1] 98±12.5; 92 [86-108]
TLC (L) 3.5±1.3; 3.3 [2.7-4.2] 5.2±0.8; 5 [4.5-5.5]
TLC (% pred) 60.6±18.7;  61 [49.8-71.4] 86±38; 85 [83-88.5]
DLCOsb (Hb-adjusted) (ml/min/mmHg) 9.3±4.5; 8.7 [7.1-11.5] 24±6; 24 [19-28]
DLCOsb (Hb-adjiusted) (% predicted) 41.9±17.8; 41 [33.2-50.6] 86±5; 84.5 [81-88]
6 MWT distance*, m 405±139; 432 [325-492] -
CPI 50.4±13.3; 53.4 [42.7-56.1] -
GAP score I (14); II (12); III (3) -
Kazerooni score
Ground glass opacities 2.5±1.8; 2 [1-4] -
Fibrosis 9.6±4.2; 8 [6-12.2] -
Data are expressed as mean±SD; median [IQR25-IQR75]
Abbreviations: pO2= arterial O2 partial pressure; sO2= arterial O2 saturation; FVC= forced vital capacity; DLCOsb=  single breath diffusing
capacity for carbon monoxide; Hb= haemoglobin; TLC= total lung capacity; 6 MWT= six-minute walk test (* data available for 15 patients);
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are also reported for IPF patients. The local Ethics
Committee approved the study and all participants
provided written informed consent. Liver imaging
analysis and TUE were realized under fasting condi-
tions by two independent operators by means of
conventional ultrasound examination (Philips iU 22,
Eindhoven, The Netherlands) and FibroScan
(EchoSens, Paris, France), respectively. Abdominal
ultrasonography was performed with a convex mul-
tifrequency transducer of 1-5 MHz to detect any
sign suggestive of liver cirrhosis (irregular surface,
coarse texture, attenuated hepatic veins) and/or of
portal hypertension (presence of abdominal collater-
als, splenomegaly), ascites and to exclude hepatic fo-
cal lesions. Liver stiffness measurements (LSMs)
were realized as follows: up to ten acquisitions were
performed on each patient. Success rate was calcu-
lated as the ratio of the number of successful acqui-
sitions over the total number of acquisitions. The
median value of successful measurements was kept as
representative of the liver stiffness. Only LSMs ob-
tained with a success rate of at least 60% were con-
sidered reliable. The median value of successful mea-
surements was considered representative for the liv-
er stiffness in a given patient if the interquartile
range of the examinations was less than 30% of the
median (11). Serum levels of alanine aminotrans-
ferase, aspartate aminotransferase, total and direct
bilirubin, albumin, alpha-fetoprotein, total choles-
terol and tryglicerides levels, prothrombin time and
concentration, along with hepatitis B virus (HBV)
and HCV antibodies were preliminary analyzed in
all subjects. HBV or HCV infection and alcohol
abuse were exclusion criteria. Total IgG and IgG
subsets serum levels were also determined. Increased
IgG4 titers were recorded in no cases. 
No remarkable alterations of liver-related para-
meters measured at the serum level were found in
the study groups (data not shown). According to the
criteria of Quyyum et al. evaluating the degree of liv-
er steatosis on a five-point scale, that is 0 (absent), 1
(minimal), 2 (mild), 3 (moderate), and 4 (severe)
based on liver echogenicity (12), mild/moderate
steatosis was identified in respectively 1 control sub-
ject and 8 IPF cases (6.6% and 27.5%). Severe
steatosis was detected in 2 IPF patients (7%), with-
out additional pathologic findings. LSMs were suc-
cessfully collected in all subjects analyzed. Mean
TUE measurements were 5.2±0.4 kPa in the control
group as compared to 6.4±2.2 kPa in IPF patients
(p=0.02, two tails unpaired t test Welch corrected);
to date, higher values were recorded in 11 IPF cases
(38%), suggesting increased liver stiffness (8.2±1.9
kPa). Stratification of IPF patients according to liv-
Table 3. Respiratory function parameters and thorax HRCT scoring in IPF patients according to liver stiffness
Parameter IPF patients with no increased liver stiffness IPF patients with increased liver stiffness
pO2 (mmHg)(21% FiO2 at rest) 68.4±11.3; 72.3 [64-75.8] 73.2±14.3; 76 [69.9-81]
FVC (% pred) 69.4±19.8; 66 [52-82.5] 65.5±15.4; 64 [57.5-73.2]
TLC (% pred) 58±17.3; 57.5 [45.5-67.7] 60.7±15.7; 58.5 [52.7-69]
DLCOsb (Hb-adjiusted) (% pred) 42.7±12.2; 44 [35-47] 53.7±22.7; 51.2 [43.5-65.5]
6 MWT distance*, m 443±78; 464 [412-490] 377±133; 396 [320-462]
sPAP, mmHg 31.5±6.2; 30 [26-35] 28.7±7.4; 25 [25-30]
CPI 51.3±11.4; 53.6 [46.7-56.8] 44.1±18.2; 43.8 [31-54.1]
GAP score I (8), II (7); III (2) I (6), II (5); III (1)
Kazerooni score
Ground glass opacities 2.3±2; 2 [1-3.75] 2.5±1.6; 2 [2-3]
Fibrosis 9.7±3.8; 9.5 [6.5-12.7] 7.8±2.8; 7 [6-8]
Any treatment (n)
- pirfenidone (2403 mg/day) 5 4
- NAC (1800 mg/day) 3 4
- other (experimental trial drugs) 1 1
- no therapy 9 6
Data are expressed as mean±SD; median [IQR25-IQR75]
Abbreviations: pO2= arterial O2 partial pressure; sO2= arterial O2 saturation; FVC= forced vital capacity; DLCOsb= single breath diffusing ca-
pacity for carbon monoxide; Hb= haemoglobin; TLC= total lung capacity; 6 MWT= six-minute walk test (* data available for 15 patients);
CPI= composite physiologic index; sPAP= systolic pulmonary artery pressure. Comparisons were not significant. 
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er stiffness values (normal versus increased) is sum-
marized in Table 3. As reported, no substantial dif-
ferences occurred in terms of lung function parame-
ters, disease and HRCT scoring, treatment or mor-
tality.
Discussion
In the present study, hepatic elastography was
used to evaluate the liver stiffness values in clinically
stable IPF patients in a real life setting. To our
knowledge, there are no available reports about the
use of non-invasive methods to early predict the liv-
er involvement in this scenario. TUE has recently
been approved in the US and widely used instead of
liver biopsy as an alternative tool for diagnosis and
monitoring of non-significant fibrosis or severe fi-
brosis/cirrhosis in patients with chronic HCV infec-
tion (6). This preliminary small case series suggests
that increased liver stiffness may be present in ap-
proximately more than one-third of IPF patients.
Unfortunately, liver biopsy was not performed in our
study due to ethical reasons: as a consequence, it was
not possible to ascertain which histo-pathological
components contributed to these findings. Further-
more, although TUE has a high degree of accuracy
and reproducibility in prediction of liver fibrosis in
the context of HCV infection, there are conflicting
reports as to the impact of steatosis on FibroScan
measurements. Arena et al. observed no influence of
steatosis on TUE (13), whereas Sanchez-Conde et
al. (14) and Boursier et al. (15) noted significant as-
sociations, especially among patients with high-grade
steatosis. This was not the case in our pilot study, as
only two IPF patients had a severe degree of steato-
sis but both of them were recorded to have normal
liver stiffness values. Further confounding factors
likely affecting liver stiffness were also investigated.
To date, clinical and instrumental findings suggestive
of right heart insufficiency were carefully excluded in
all patients. Not surprisingly, no significant correla-
tions were found between liver stiffness and lung
function parameters. Similarly, no association was
observed with other disease severity indices, that are
the CPI and the Kazerooni score. This may be de-
pendent on the small number of patients enrolled in
a single center setting that clearly represents a limita-
tion of our study. Conversely, up to now, the mortal-
ity rate was lower among patients with evidence of
increased liver stiffness, with this finding not having
a clear explanation. Again, our feeling is that such an
observation may be not conclusive as comorbidities
and longer disease duration cannot be ruled out as
outcome determinants in patients with no signs of
any liver involvement. Addressing this issue needs
longitudinal efforts in larger study populations. 
In conclusion, as IPF is still considered a rare
disease requiring a multi-disciplinary diagnostic
process, we strongly believe that any effort improv-
ing knowledge in such a challenging scenario should
be encouraged. We do not really believe that IPF is
a systemic disease and our preliminary data are not
sufficient to support such an hypothesis. To our
knowledge, this is the first attempt to incorporate
into clinical practice novel methodologies aimed at
delineating in a more comprehensive fashion the
complex IPF clinical phenotype. Apart from several
limitations, it could pave the way to prospective con-
firmation studies in larger patient samples. The role
of genetic factors, including telomere shortening, is
also an issue to be investigated (16). The clinical rel-
evance and the likely involvement of additional or-
gans (i.e, kidney, heart) should be addressed as well.
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